Zealand Pharma A/S (ZEAL +0.3%) initiates a second Phase 3 clinical trial assessing soluble glucagon analog dasiglucagon for the rescue treatment of severe hypoglycemia (low blood sugar) in type 1 diabetics.
The study's objective is to confirm rapid plasma glucose increase after a single administration of dasiglucagon in T1D patients with insulin-induced hypoglycemia.
The first Phase 3 was launched in July with enrollment completed in October. Topline results should be available in Q2 2018.
Dasiglucagon has Orphan Drug status for the indication in the U.S. and Europe.
Now read: Geron: It's Breakout Time »